Symbols / CRDL Stock $1.30 -1.52% Cardiol Therapeutics Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • Canada • NCM
CRDL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. David G. Elsley MBA
Exch · Country NCM · Canada
Market Cap 145.18M
Enterprise Value 126.38M
Income -33.82M
Sales —
FCF (ttm) -13.03M
Book/sh 0.13
Cash/sh 0.19
Employees —
Insider 10d —
IPO Jan 15, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.48
PEG —
P/S —
P/B 9.99
P/C —
EV/EBITDA -3.69
EV/Sales —
Quick Ratio 3.83
Current Ratio 4.16
Debt/Eq 0.70
LT Debt/Eq —
EPS (ttm) -0.29
EPS next Y -0.17
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-31
ROA -77.31%
ROE -158.75%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 111.68M
Shs Float 96.49M
Insider Own 2.43%
Instit Own 21.90%
Short Float 1.82%
Short Ratio 1.98
Short Interest 1.98M
52W High 1.71
vs 52W High -23.98%
52W Low 0.88
vs 52W Low 47.73%
Beta 0.42
Impl. Vol. 15.42%
Rel Volume 0.65
Avg Volume 677.70K
Volume 438.05K
Target (mean) $7.41
Tgt Median $7.73
Tgt Low $5.01
Tgt High $9.17
# Analysts 4
Recom Strong_buy
Prev Close $1.32
Price $1.30
Change -1.52%
About

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.42
Mean price target
2. Current target
$1.31
Latest analyst target
3. DCF / Fair value
$-2.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.31
Low
$5.02
High
$9.19
Mean
$7.42

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-06 main Canaccord Genuity Buy → Buy $8
2026-02-10 reit HC Wainwright & Co. Buy → Buy $9
2025-12-01 reit HC Wainwright & Co. Buy → Buy $9
2025-06-02 init HC Wainwright & Co. — → Buy $9
2025-04-16 reit HC Wainwright & Co. Buy → Buy $9
2025-04-07 reit HC Wainwright & Co. Buy → Buy $9
2025-02-24 reit HC Wainwright & Co. Buy → Buy $9
2024-12-18 reit HC Wainwright & Co. Buy → Buy $9
2024-11-20 reit HC Wainwright & Co. Buy → Buy $9
2024-10-24 reit HC Wainwright & Co. Buy → Buy $9
2024-06-26 init Roth MKM — → Buy $10
2024-06-14 reit HC Wainwright & Co. Buy → Buy $9
2024-06-07 reit HC Wainwright & Co. Buy → Buy $9
2024-05-23 main Canaccord Genuity Buy → Buy $8
2024-05-14 reit HC Wainwright & Co. Buy → Buy $9
2024-04-22 init HC Wainwright & Co. — → Buy $9
News
RSS: Latest CRDL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-17 Elsley (David) Director of Issuer — 100,000 $1.00 $100,000
2025-10-17 Torreamione (Guilermo) Senior Officer of Issuer — 50,000 $1.00 $50,000
2025-10-01 Hamer (Andrew Warwick M.D.) Senior Officer of Issuer — 133,334 — —
2025-09-08 Chao (Jennifer M) Director of Issuer — 13,334 — —
2025-09-08 Hamer (Andrew Warwick M.D.) Senior Officer of Issuer — 70,000 — —
2025-09-08 Loxam (Teri) Director of Issuer — 13,334 — —
2025-05-28 Garnett (Timothy John) Director of Issuer — 0 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
34.32
-14.80%
40.28
+35.22%
29.79
-27.94%
41.34
Research And Development
14.02
+0.05%
14.01
-1.49%
14.22
-24.99%
18.96
Selling General And Administration
20.20
-22.00%
25.89
+66.38%
15.56
-30.45%
22.37
General And Administrative Expense
20.20
-22.00%
25.89
+66.38%
15.56
-30.45%
22.37
Salaries And Wages
9.22
-28.59%
12.92
—
—
Other Gand A
10.97
-15.44%
12.97
-16.62%
15.56
-30.45%
22.37
Total Expenses
34.32
-14.80%
40.28
+35.22%
29.79
-27.94%
41.34
Operating Income
-34.32
+14.80%
-40.28
-35.22%
-29.79
+27.94%
-41.34
EBITDA
-34.21
+14.26%
-39.90
-35.10%
-29.54
+28.16%
-41.12
Normalized EBITDA
-33.99
+19.62%
-42.28
-45.77%
-29.01
+42.13%
-50.12
Reconciled Depreciation
0.10
-72.67%
0.37
+50.23%
0.25
+12.94%
0.22
EBIT
-34.32
+14.80%
-40.28
-35.22%
-29.79
+27.94%
-41.34
Total Unusual Items
-0.23
-109.63%
2.38
+547.80%
-0.53
-105.90%
9.00
Total Unusual Items Excluding Goodwill
-0.23
-109.63%
2.38
+547.80%
-0.53
-105.90%
9.00
Net Income
-33.82
+7.79%
-36.68
-30.39%
-28.13
+9.06%
-30.93
Pretax Income
-33.82
+7.79%
-36.68
-30.39%
-28.13
+9.06%
-30.93
Net Non Operating Interest Income Expense
0.73
-39.13%
1.19
-41.46%
2.04
+64.71%
1.24
Net Interest Income
0.73
-39.13%
1.19
-41.46%
2.04
+64.71%
1.24
Interest Income Non Operating
0.73
-39.13%
1.19
-41.46%
2.04
+64.71%
1.24
Interest Income
0.73
-39.13%
1.19
-41.46%
2.04
+64.71%
1.24
Other Income Expense
-0.23
-109.52%
2.41
+731.08%
-0.38
-104.16%
9.17
Other Non Operating Income Expenses
—
0.03
-81.15%
0.15
-8.94%
0.16
Gain On Sale Of Security
-0.23
-109.63%
2.38
+547.80%
-0.53
-105.90%
9.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-33.82
+7.79%
-36.68
-30.39%
-28.13
+9.06%
-30.93
Net Income From Continuing Operation Net Minority Interest
-33.82
+7.79%
-36.68
-30.39%
-28.13
+9.06%
-30.93
Net Income From Continuing And Discontinued Operation
-33.82
+7.79%
-36.68
-30.39%
-28.13
+9.06%
-30.93
Net Income Continuous Operations
-33.82
+7.79%
-36.68
-30.39%
-28.13
+9.06%
-30.93
Normalized Income
-33.59
+13.99%
-39.06
-41.52%
-27.60
+30.89%
-39.93
Net Income Common Stockholders
-33.82
+7.79%
-36.68
-30.39%
-28.13
+9.06%
-30.93
Diluted EPS
-0.39
+23.53%
-0.51
-15.91%
-0.44
+10.20%
-0.49
Basic EPS
-0.39
+23.53%
-0.51
-15.91%
-0.44
+10.20%
-0.49
Basic Average Shares
86.99
+21.55%
71.57
+11.02%
64.46
+3.13%
62.51
Diluted Average Shares
86.99
+21.55%
71.57
+11.02%
64.46
+3.13%
62.51
Diluted NI Availto Com Stockholders
-33.82
+7.79%
-36.68
-30.39%
-28.13
+9.06%
-30.93
Amortization
0.00
-100.00%
0.21
—
—
Amortization Of Intangibles Income Statement
0.00
-100.00%
0.21
—
—
Depreciation Amortization Depletion Income Statement
0.10
-72.67%
0.37
—
—
Depreciation And Amortization In Income Statement
0.10
-72.67%
0.37
—
—
Depreciation Income Statement
0.10
-37.34%
0.16
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
23.62
-25.87%
31.86
-13.18%
36.70
-40.83%
62.03
Current Assets
23.50
-25.79%
31.67
-12.41%
36.15
-41.16%
61.44
Cash Cash Equivalents And Short Term Investments
21.42
-29.97%
30.58
-12.46%
34.93
-41.26%
59.47
Cash And Cash Equivalents
21.42
-29.97%
30.58
-12.46%
34.93
-41.26%
59.47
Receivables
0.23
-37.45%
0.36
+29.21%
0.28
-41.72%
0.48
Accounts Receivable
0.06
-44.48%
0.10
-29.69%
0.14
-32.00%
0.21
Other Receivables
0.17
-34.75%
0.26
+90.52%
0.14
-49.26%
0.27
Prepaid Assets
1.86
+155.88%
0.73
-22.83%
0.94
-36.73%
1.49
Total Non Current Assets
0.12
-39.62%
0.20
-64.27%
0.55
-7.30%
0.59
Net PPE
0.12
-39.62%
0.20
-41.97%
0.34
+13.97%
0.30
Gross PPE
0.99
+2.53%
0.97
-2.57%
0.99
+26.03%
0.79
Accumulated Depreciation
-0.87
-13.20%
-0.77
-17.65%
-0.66
-33.26%
-0.49
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.24
+11.29%
0.22
+10.89%
0.20
+9.14%
0.18
Other Properties
0.51
+0.00%
0.51
-8.35%
0.56
+50.74%
0.37
Leases
0.24
+0.00%
0.24
+0.00%
0.24
+0.00%
0.24
Goodwill And Other Intangible Assets
—
0.00
-100.00%
0.21
-28.64%
0.29
Other Intangible Assets
—
—
0.21
-28.64%
0.29
Total Liabilities Net Minority Interest
5.74
-19.52%
7.14
-15.60%
8.45
-13.97%
9.83
Current Liabilities
5.66
-19.33%
7.01
-15.50%
8.30
-15.39%
9.80
Payables And Accrued Expenses
3.48
-50.14%
6.98
-13.24%
8.04
-13.85%
9.33
Current Debt And Capital Lease Obligation
0.04
+16.17%
0.03
+108.81%
0.02
-68.66%
0.05
Current Capital Lease Obligation
0.04
+16.17%
0.03
+108.81%
0.02
-68.66%
0.05
Other Current Liabilities
2.14
—
0.24
-43.28%
0.42
Total Non Current Liabilities Net Minority Interest
0.09
-30.55%
0.13
-20.82%
0.16
+606.97%
0.02
Long Term Debt And Capital Lease Obligation
0.09
-30.55%
0.13
-20.82%
0.16
+606.97%
0.02
Long Term Capital Lease Obligation
0.09
-30.55%
0.13
-20.82%
0.16
+606.97%
0.02
Stockholders Equity
17.88
-27.70%
24.73
-12.45%
28.25
-45.89%
52.20
Common Stock Equity
17.88
-27.70%
24.73
-12.45%
28.25
-45.89%
52.20
Capital Stock
201.87
+12.56%
179.34
+20.75%
148.52
+0.66%
147.55
Common Stock
201.87
+12.56%
179.34
+20.75%
148.52
+0.66%
147.55
Share Issued
100.26
+21.36%
82.61
+26.41%
65.35
+2.05%
64.04
Ordinary Shares Number
100.26
+21.36%
82.61
+26.41%
65.35
+2.05%
64.04
Additional Paid In Capital
29.08
+18.00%
24.65
+31.20%
18.79
+20.53%
15.59
Retained Earnings
-213.07
-18.87%
-179.25
-25.72%
-142.58
-24.58%
-114.45
Total Equity Gross Minority Interest
17.88
-27.70%
24.73
-12.45%
28.25
-45.89%
52.20
Total Capitalization
17.88
-27.70%
24.73
-12.45%
28.25
-45.89%
52.20
Working Capital
17.85
-27.62%
24.66
-11.48%
27.86
-46.05%
51.63
Invested Capital
17.88
-27.70%
24.73
-12.45%
28.25
-45.89%
52.20
Total Debt
0.13
-20.82%
0.16
-9.07%
0.17
+139.24%
0.07
Capital Lease Obligations
0.13
-20.82%
0.16
-9.07%
0.17
+139.24%
0.07
Net Tangible Assets
17.88
-27.70%
24.73
-11.80%
28.04
-45.99%
51.91
Tangible Book Value
17.88
-27.70%
24.73
-11.80%
28.04
-45.99%
51.91
Other Equity Interest
—
—
3.52
+0.00%
3.52
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-23.85
+4.81%
-25.06
+0.47%
-25.18
+7.49%
-27.22
Cash Flow From Continuing Operating Activities
-23.85
+4.81%
-25.06
+0.47%
-25.18
+7.49%
-27.22
Net Income From Continuing Operations
-33.82
+7.79%
-36.68
-30.39%
-28.13
+9.06%
-30.93
Depreciation Amortization Depletion
0.10
-72.67%
0.37
+50.23%
0.25
+12.94%
0.22
Depreciation
0.10
-37.34%
0.16
-0.70%
0.16
+21.00%
0.14
Amortization Cash Flow
0.00
-100.00%
0.21
+149.11%
0.08
+0.00%
0.08
Depreciation And Amortization
0.10
-72.67%
0.37
+50.23%
0.25
+12.94%
0.22
Amortization Of Intangibles
0.00
-100.00%
0.21
+149.11%
0.08
+0.00%
0.08
Other Non Cash Items
0.02
-13.05%
0.03
-20.54%
0.03
-93.94%
0.53
Stock Based Compensation
10.70
-25.05%
14.28
+243.47%
4.16
-17.08%
5.01
Operating Gains Losses
-0.13
+94.00%
-2.13
-125.51%
-0.94
+87.91%
-7.81
Gain Loss On Investment Securities
-0.95
-299.60%
-0.24
-31.06%
-0.18
+96.28%
-4.89
Net Foreign Currency Exchange Gain Loss
0.82
+143.60%
-1.89
-148.03%
-0.76
+73.90%
-2.92
Change In Working Capital
-0.73
+21.28%
-0.93
-70.65%
-0.55
-109.50%
5.75
Change In Receivables
0.14
+265.66%
-0.08
-140.81%
0.20
+374.15%
-0.07
Changes In Account Receivables
0.04
+5.33%
0.04
-36.92%
0.07
+146.59%
-0.14
Change In Inventory
—
—
0.00
0.00
Change In Prepaid Assets
-1.13
-626.89%
0.21
-60.67%
0.55
-59.41%
1.35
Change In Payables And Accrued Expense
0.26
+124.77%
-1.06
+17.63%
-1.29
-128.89%
4.47
Investing Cash Flow
-0.02
-15.00%
-0.02
+66.90%
-0.06
+13.92%
-0.07
Cash Flow From Continuing Investing Activities
-0.02
-15.00%
-0.02
+66.90%
-0.06
+13.92%
-0.07
Net PPE Purchase And Sale
-0.02
-15.00%
-0.02
+66.90%
-0.06
+13.92%
-0.07
Purchase Of PPE
-0.02
-15.00%
-0.02
+66.90%
-0.06
+13.92%
-0.07
Capital Expenditure
-0.02
-15.00%
-0.02
+66.90%
-0.06
+13.92%
-0.07
Financing Cash Flow
15.54
-17.52%
18.84
+34122.57%
-0.06
-2.67%
-0.05
Cash Flow From Continuing Financing Activities
15.54
-17.52%
18.84
+34122.57%
-0.06
-2.67%
-0.05
Net Issuance Payments Of Debt
-0.06
-33.33%
-0.04
+25.00%
-0.06
-2.67%
-0.05
Repayment Of Debt
-0.06
-33.33%
-0.04
+25.00%
-0.06
-2.67%
-0.05
Long Term Debt Payments
-0.06
-33.33%
-0.04
+25.00%
-0.06
-2.67%
-0.05
Net Long Term Debt Issuance
-0.06
-33.33%
-0.04
+25.00%
-0.06
-2.67%
-0.05
Net Common Stock Issuance
16.04
-24.90%
21.36
0.00
0.00
Proceeds From Stock Option Exercised
0.03
-80.70%
0.18
0.00
0.00
Net Other Financing Charges
-0.48
+82.01%
-2.65
—
—
Changes In Cash
-8.34
-33.60%
-6.24
+75.33%
-25.30
+7.49%
-27.35
Effect Of Exchange Rate Changes
-0.82
-143.60%
1.89
+148.03%
0.76
-73.90%
2.92
Beginning Cash Position
30.58
-12.46%
34.93
-41.26%
59.47
-29.12%
83.90
End Cash Position
21.42
-29.97%
30.58
-12.46%
34.93
-41.26%
59.47
Free Cash Flow
-23.88
+4.80%
-25.08
+0.64%
-25.24
+7.51%
-27.30
Common Stock Issuance
16.04
-24.90%
21.36
0.00
0.00
Issuance Of Capital Stock
16.04
-24.90%
21.36
0.00
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category